Hetero's new Favivir packaging for Covid-19 with 800 mg dosage cuts pill burden

▴ Hetero's new Favivir packaging for Covid-19 with 800 mg dosage cuts pill burden
The higher strength of Favipiravir 800 mg from Hetero has been approved by the Drug Controller General of India

Hetero, one of India's leading generic pharmaceutical companies and the world's largest producer of anti-retroviral drugs, on Friday announced the launch of first-ever "patient compliant pack" of Favivir 800/200 for the treatment of mild-to-moderate symptomatic Covid-19 patients in India.

Favivir 800/200 will be available in a patient-friendly pack containing 16 tablets of Favipiravir 800mg and 2 tablets of Favipiravir 200mg. It is priced at Rs 2,640.


The higher strength of Favipiravir 800 mg from Hetero has been approved by the Drug Controller General of India (DCGI). The product will be marketed and distributed by Hetero Healthcare Ltd, the company said in a statement.

The launch of 'Favivir 800/200' is aimed at enhancing patients' adherence to treatment regimen by reducing the number of pills they are required to consume per day, it said.

The initial regimen of Favipiravir 200mg requires patients to consume a total of 122 tablets for the 14-day treatment course. However, with the new Favivir 800/200 pack, the pill intake number is reduced to 32 tablets, effectively cutting down the pill burden by nearly 75 per cent, leading to better treatment outcomes.


Favivir is the second drug developed by Hetero after Covifor (Remdesivir) used in the treatment of Covid-19. It is an oral antiviral medication that has shown positive clinical outcomes. The product will be made available at all retail medical outlets and hospital pharmacies across the country and will be sold only on prescription.

Tags : #Favivir #Favivir800mg #Favivir800mgPricing #Hetero #FavipiravirbyHetero #Remdesivir #PatientCompliantPack #LatestPharmaNewsUpdateSep26 #LatestCovidDrugNewsSep26

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

To stay well during festive seasonOctober 21, 2020
The fastest growing and the most awarded Cath Lab of India in 2018 is bringing affordable and accessible healthcare available for cardiovascular diseases in India saOctober 21, 2020
ViiV healthcare development program on cabotegravir and rilivirine has no pandemic interruptionsOctober 21, 2020
No significant clinical benefit with Umifenovir addition in COVID-19 treatment: Glenmark clinical study October 21, 2020
India sustains the continued trend of consistent decline in Active CasesOctober 21, 2020
Lifeness Science Institute by Luke Coutinho Introduces Programmes in Integrative Nutrition and DieteticsOctober 21, 2020
Lifeness Science Institute by Luke Coutinho Introduces Programmes in Integrative Nutrition and DieteticsOctober 21, 2020
Haryana tops Anemia Mukt Bharat Index in countryOctober 21, 2020
Covid Update: Assam & OdishaOctober 21, 2020
BriaCell announces the overall breast cancer survival (OS) data of its lead product candidate, Bria-IMT™October 21, 2020
Teladoc Health Data Shows Broadening Mental Health Care DemandOctober 21, 2020
China vaccinated 60,000 people: Result awaited October 21, 2020
Lilly hires outside advisor for COVID drug plant problemsOctober 21, 2020
No Child Mothers, Accelerating the reduction of adolescent pregnancies on occasion of Adolescent Pregnancy Prevention Week October 21, 2020
Tyber Medical receives US FDA clearance on foot and ankle plating systemsOctober 21, 2020
Green tea and coffee connected to lower death risk in people with diabetesOctober 21, 2020
MEDICAL FESTIVAL ASIA: Events for the region’s medical and healthcare sectorOctober 21, 2020
Selecta Biosciences and Asklepios BioPharmaceutical receives US FDA approval for their gene therapyOctober 21, 2020
Astellas Pharma received US FDA approval for the treatment of primary mitochondrial myopathiesOctober 21, 2020
GSK presents positive clinical data on maternal and older adults RSV candidate vaccinesOctober 21, 2020